Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 57Prostatic Neoplasms, Castration-Resistant 4Metastatic Castration-resistant Prostate Cancer 3Prostate Cancer Metastatic 2Neoplasm Metastasis 2Metastatic Castration-Resistant Prostate Cancer 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Sleep Initiation and Maintenance Disorders 1Prostatic Diseases 1Prostate Adenocarcinoma 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoplasms 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone Refractory Prostate Cancer 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Neoplasms, Male 1Fatigue 1Depression 1Dementia 1Cognitive Dysfunction 1Carcinoma, Transitional Cell 1

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Refractory Prostate Cancer × Abiraterone Acetate × 1 year × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡